fig4

Figure 4. Flow cytometry results of THP-1 cells treated with CM from ZEB2 knockdown PC9-GR and HCC827-GR cells and tumor tissues from ZEB2 knockout PC9-GR or HCC827-GR CDX mouse models. (A and B) PC9-GR and HCC827-GR with or without ZEB2 knockout were inoculated into the right flanks of mice subcutaneously at a concentration of 1 × 10⁶ cells/100 μL. The sizes of tumors were measured every four days by caliper and five measurements during the experiment were presented as mean ± SD (n = 3 mice/group); (C and D) PC9-GR and HCC827-GR with or without ZEB2 knockout were inoculated into the right flanks of mice subcutaneously at a concentration of 1 × 10⁶ cells/100 μL. The weights of mice were recorded every four days and five results during the experiment were presented as mean ± SD (n = 3 mice/group); (E) Tumor images from each mouse are displayed; (F and G) The percentages of CD206⁺ and CD86⁺ TAMs in F4/80⁺ TAMs in tumor tissues from PC9-GR or HCC827-GR with or without ZEB2 knockout CDX mouse models were analyzed by flow cytometry; (F) Representative pseudo-color plots presenting the process of gating; (G) Average results from three independent experiments. ^*P < 0.05, ^**P < 0.005, ^***P < 0.0005.